FDA Failures During Heparin Crisis Drive Congress’ Stronger Drug Safety Push
This article was originally published in The Tan Sheet
Executive Summary
FDA's role in the handling of contaminated-heparin crisis is illustrative of "the best and the worst" of its performance under the administration, said David Nelson, senior investigator for the House Energy and Commerce Committee
You may also be interested in...
Globalization Act’s Drug Safety Provisions Look Harmful For Industry
The FDA Globalization Act could be devastating to the drug industry while not creating the safety improvements that Congress expects, according to former FDA attorneys
Globalization Act’s Drug Safety Provisions Look Harmful For Industry
The FDA Globalization Act could be devastating to the drug industry while not creating the safety improvements that Congress expects, according to former FDA attorneys
Globalization Act’s Drug Safety Provisions Look Harmful For Industry
The FDA Globalization Act could be devastating to the drug industry while not creating the safety improvements that Congress expects, according to former FDA attorneys